News | January 12, 2022
Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra
Ind-Ra expects revenue growth of over 12% in 2022.
Ind-Ra expects revenue growth of over 12% in 2022.
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
Flattish volume growth and subdued new launches were key factors for last month
Healtherbs helps in restoring the desired energy levels for daily activity and immunity
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
_256_384.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
Sudeep Nutrition will be a one-stop solution for food, beverage, nutraceuticals and nutritional product manufacturers
Subscribe To Our Newsletter & Stay Updated
